Unum Therapeutics (NASDAQ:UMRX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday.
According to Zacks, “Unum Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel immunotherapy products of immune system to cure cancer. The company’s program consists of ACTR087 rituximab, ACTR707 RITUXIMAB, ACTR087 SEA-BCMA which are in clinical stage. Unum Therapeutics Inc. is based in Cambridge, United States. “
Other equities research analysts also recently issued reports about the company. HC Wainwright started coverage on Unum Therapeutics in a report on Thursday, December 20th. They set a “buy” rating and a $18.00 target price on the stock. Cowen reiterated a “hold” rating on shares of Unum Therapeutics in a report on Monday, November 19th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Unum Therapeutics currently has an average rating of “Buy” and an average target price of $20.00.
In other Unum Therapeutics news, insider Seth Ettenberg sold 11,485 shares of the firm’s stock in a transaction that occurred on Wednesday, December 26th. The stock was sold at an average price of $4.05, for a total transaction of $46,514.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Hedge funds and other institutional investors have recently modified their holdings of the business. Bank of New York Mellon Corp acquired a new stake in Unum Therapeutics during the 2nd quarter valued at approximately $177,000. American International Group Inc. grew its position in shares of Unum Therapeutics by 432.8% in the 4th quarter. American International Group Inc. now owns 12,531 shares of the company’s stock worth $55,000 after acquiring an additional 10,179 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Unum Therapeutics in the 3rd quarter worth approximately $150,000. JPMorgan Chase & Co. grew its position in shares of Unum Therapeutics by 2,782.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 20,753 shares of the company’s stock worth $213,000 after acquiring an additional 20,033 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new position in shares of Unum Therapeutics in the 3rd quarter worth approximately $235,000. Hedge funds and other institutional investors own 53.65% of the company’s stock.
Unum Therapeutics Company Profile
Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma.
Featured Article: Dividend Aristocrat Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.